Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Cheng Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Hydrochlorothiazide, Skin Neoplasms, Drug Labeling, United States Food and Drug Administration. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: U.S. Food and Drug Administration, FDA HHS, Food and Drug Administration.
Abstract (Originalsprache)
Purpose
On August 20, 2020, the United States (U.S.) Food and Drug Administration (FDA) issued a Drug Safety Communication (DSC) along with labeling updates to inform the public about a small increased risk of non‐melanoma skin cancer (NMSC) associated with hydrochlorothiazide (HCTZ) use. This study aims to assess whether the DSC impacted HCTZ use in the U.S.
Methods
We conducted a trend analysis in the Sentinel Distributed Database using national healthcare administrative data from January 2017 to November 2022. We identified two cohorts each month: An overall cohort of all enrollees and a skin cancer cohort of those with a history of NMSC. For each cohort, we plotted the monthly proportion of patients receiving HCTZ‐containing products among those receiving any thiazide diuretics. We performed interrupted time series analyses to quantify the impact of the DSC on these monthly proportions. Secondary analyses were conducted on the proportion of HCTZ users among patients receiving any antihypertensives.
Results
In the overall cohort, the DSC was only associated with a statistically significant but clinically negligible trend change of monthly HCTZ proportion within this cohort (0.018%; 95% CI, 0.012%–0.025%). Similar results were observed in the skin cancer cohort. The secondary analysis found no significant level change or trend change in the monthly proportion of HCTZ use among antihypertensive users.
Conclusions
We did not observe significant changes in HCTZ use following the DSC about its NMSC risk, among the overall population and those with a history of NMSC. Our findings were in accordance with the DSC recommendation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
- Epidemiology and Drug Safety, IQVIA Real World Solutions, Washington, DC, USA.
- Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Cardiology and Nephrology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Cheng Chen, Mingfeng Zhang
Förderung
- U.S. Food and Drug Administration
- FDA HHS
- Food and Drug Administration
Zitieren
APA
Chen, C., Eworuke, E., Rai, A., Hou, L., Ko, J. S., Southworth, M. R., Hernández-Muñoz, J. J., & Zhang, M. (2024). Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70040
Vancouver
Chen C, Eworuke E, Rai A, Hou L, Ko JS, Southworth MR, et al. Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70040
BibTeX
@article{Chen2024,
author = {Chen, Cheng and Eworuke, Efe and Rai, Ashish and Hou, Laura and Ko, Jenice S and Southworth, Mary Ross and Hernández-Muñoz, José J and Zhang, Mingfeng},
title = {Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.70040}
}
EUVIMED